However, owing to several manufacturing related complexities, many contemporary drug developers have demonstrated a preference to rely on CMOs for the supply of GMP grade lipids.

The lipid contract manufacturing market size reaches USD 5.6 billion by 2030, growing at a CAGR of 10%.

Key Market Insights

Around 60 companies claim to offer contract manufacturing services for lipids

The majority (39%) of the industry stakeholders are mid-sized companies, followed by small players (32%) and large / very large firms (29%). In addition, 35% of the CMOs engaged in this domain offer services for liposomes / lipid nanoparticles, followed by those providing services for phospholipids (17%).

Several partnerships were established in this domain, during the period 2016-2021

Acquisitions and manufacturing agreements (23% each) emerged as the most common types of partnership models adopted by stakeholders engaged in this domain. Majority (49%) of the deals were inked for lipid-based FDFs, followed by those signed for lipid-based excipients (30%).

Expansion activity in this domain has grown at a CAGR of ~55%, between 2016 and 2021

Most of such initiatives were focused on the establishment of new facilities (35%) and expanding existing facilities (35%), followed by those carried out for capacity expansion (30%). Further, majority of the investments were made in facilities located in North America (67%) and Europe (28%).

Currently available lipid contract manufacturing capacity is estimated to be over 0.1 million liters

Around 40% of the total capacity is installed for carrying out commercial scale operations. Further, in terms of geography, the maximum lipid contract manufacturing capacity (close to 65%) is installed in North America.

North America and Europe are anticipated to capture close to 70% of the market share, by 2030

In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (11.4%), over the next nine years. Further, in 2030, the majority share (~55%) of contract manufacturing revenues is likely to be generated from projects focused on liposomes / lipid nanoparticles and phospholipids.

Key Questions Answered

Who are the leading players engaged in offering lipid contract manufacturing services?

Which global regions are considered as key hubs for contract manufacturing of lipid products?

Which partnership models are most commonly adopted by stakeholders in this industry?

What different expansion initiatives have been undertaken by lipid contract manufacturers?

Which factors are likely to influence the decision of whether to carry out lipid manufacturing in-house or outsource these operations?

What is current, global lipid manufacturing capacity (in litres) of contract manufacturers?

How is the current and future market opportunity likely to be distributed across key market segments?

The USD 5.5+ billion (by 2030) financial opportunity associated with lipid contract manufacturing market has been analyzed across the following segments:

Type of Lipid

Liposomes / Lipid Nanoparticles

Phospholipids

PEGylated lipids

Ionizable lipids (Cationic / Anionic)

Triglycerides

Sphingolipids

Neutral lipids

Others

Company Size

Small

Mid-sized

Large / Very Large

Scale of Operation

Preclinical

Clinical

Commercial

Key Geographical Regions

North America

Europe

Asia Pacific

MENA

Latin America

Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, a significant proportion of manufacturing operation are presently outsourced. This can be attributed to the fact that most products in this field are specialized formulations and therefore, require advanced expertise. The report includes detailed transcripts of discussions held with the following experts:

Asha Van Rooijen (Founder and Chief Executive Officer, Liposoma)

Rahul Keswani (Associate Director, Formulation Development, Exelead)

John Riley (Director, Process Development-Chemistry, BioVectra) and Clement Mugabe (Acting Manager, Biotech Process Development, BioVectra)

The research includes profiles of key players (listed below), featuring a brief overview of the company, its financial performance (if available), details related to its service portfolio, manufacturing facilities, recent developments and an informed future outlook.

Ardena

Avanti Polar Lipids

CordenPharma

Creative Biolabs

Evonik

Exelead

FormuMax Scientific

Fresenius Kabi

Fujifilm

Merck KGaA

Nagase Medicals

Nippon Fine Chemical

T&T Scientific

TTY Biopharm

VCARE Bio Labs

Contact:

Gaurav Chaudhary

+1 (857) 387 7999
+44 (748) 188 1310

Gaurav.Chaudhary@rootsanalysis.com

Targeted protein degradation employs modalities responsible for protein destruction, offering advantages such as specificity, stability, and minimal off-target effects. Bolstered by these advantages and ongoing technological advancements, the targeted protein degradation market is expected to witness significant growth during the forecast period.

Market Segments

Based on the type of degrader, the market is segmented into SERDs, PROTACs and Molecular Glues

SERDs are likely to lead the market for targeted protein degradation, capturing the largest revenue share in 2024.

PROTACs are anticipated to show the highest growth rate during the forecast period of around 28% annually.

Based on the target indication, the market is segmented into Breast Cancer and Multiple Myeloma

Targeted protein degradation therapies intended for breast cancer led the market for targeted protein degradation, capturing the largest revenue share in 2024.

Targeted protein degradation therapies intended for breast cancer are anticipated to show the highest growth rate during the forecast period of around 30% annually.

Targeted Protein Degradation Market Regional Outlook

Based on the key geographical regions, the market can be segmented into four major regions, including North America, Europe, Asia-Pacific and rest of the world. North America is anticipated to capture the majority share of the targeted protein degradation market in 2024 and this trend is likely to remain unchanged during the forecast period. Further, the targeted protein degradation industry in Asia-Pacific is accounted to be the fastest-growing segment of the market. This is primarily due to the increasing number of biopharmaceutical startups and likely drug approvals in the region for treatment of various oncological indications.?

Key Report Takeaways

Currently, more than 285 targeted protein degradation therapies are either approved or being investigated in different stages of development

At present, around 85 innovative targeted protein degradation technologies are available for developing stable and efficacious degraders

Around 250 clinical trials are currently underway to investigate targeted protein degradation therapies intended for treatment of various diseases, across different geographies

Grants worth over USD 165 million have been awarded since 2019; additionally, ~80% of these grants were awarded for a support period of 1-4 years

More than 985 patents have been filed / granted were focused on targeted protein degraders and related technologies, by industry and non-industry players, to protect the intellectual property generated within this field

In the last five years, several articles focused on targeted protein degraders and related technologies have been published in various high-impact journals, especially in the Asia-Pacific region

Owing to the financial prosperity and the cultural norms present in the region, the US has emerged as a hub of the established players and the new entrants in this industry

Post-2019, a considerable increase in partnership activity has been witnessed in this domain; 25% of the deals were focused on research and development of novel candidates, signed primarily by the players based in the US

Several investors have realized the opportunity within the domain of targeted protein degradation and invested around USD 13.5 billion across various funding rounds in the past six years

Owing to the protein degraders ability to degrade the undruggable targets selectively, the targeted protein degradation therapies market is anticipated to witness an annualized growth of 32%, over the next decade

The targeted protein degradation technologies market is expected to grow at an annualized rate of 7.5% between 2024 and 2035; the projected opportunity is anticipated to be well distributed across different payment models

Key Players

Examples of key companies engaged in targeted protein degradation market (which have also been profiled in this market report; the complete list of companies is available in the full report) include (in alphabetic order) Arvinas, AstraZeneca, BeiGene, Bristol-Myers Squibb, C4 Therapeutics, Eisai Therapeutics, InnoCare Pharma, Kangpu Biopharmaceuticals, Kintor Pharmaceutical, Loxo Oncology, Medivir, Monte Rosa Therapeutics, Olema Oncology, Radius Health, Ranok Therapeutics, Roche, Sanofi and Zentalis Pharmaceuticals.

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: sales@rootsanalysis.com